Naturalendo Tech Co., Ltd. (KOSDAQ:168330)

Market Cap	75.62B +17.1%
Revenue (ttm)	22.23B -0.2%
Net Income	-3.22B
EPS	-102.00
Shares Out	31.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,473,197
Average Volume	115,033
Open	2,405.00
Previous Close	2,395.00
Day's Range	2,350.00 - 3,100.00
52-Week Range	1,958.00 - 6,300.00
Beta	0.39
RSI	66.34
Earnings Date	May 22, 2026

About Naturalendo Tech

Naturalendo Tech Co., Ltd. engages in the research, development, manufacture, and sale of natural product new drugs, cosmetics, materials, food additives, and health functional food in South Korea. The company offers EstroG-100, a functional raw material for women's menopause; HabaNova, a diet material; YGF 251, a phyto height growth booster; NET 2401, a multiway sleep-wake cycle regulator; Stauntonia hexaphylla Fruit Extract, an anti-inflammatory superfood; Q.186 complex for improving male menopause; NET 1701, a ultimate men’s prostate and uri...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 81
• Stock Exchange: KOSDAQ
• Ticker Symbol: 168330

Financial Performance

In 2025, Naturalendo Tech's revenue was 22.23 billion, a decrease of -0.16% compared to the previous year's 22.26 billion. Losses were -3.22 billion, -17.10% less than in 2024.